Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$3.75 +0.8%	$4.49	$2.30 ▼ $34.00	$15.86M	1.15	36,164 shs	18,942 shs
OTLK Oncobiologics	$2.09 +6.6%	$1.91	$0.87 ▼ $8.32	$65.79M	0.26	849,200 shs	1.74 million shs
RPTX Repare Therapeutics	$1.56 +1.3%	$1.48	$0.89 ▼ $4.07	$66.16M	0.93	704,802 shs	60,241 shs
VNRX VolitionRx	$0.62	$0.69	$0.40 ▼ $0.94	$64.47M	1.26	193,792 shs	87,932 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	+4.49%	-3.12%	-20.85%	+16.61%	-87.41%
OTLK Oncobiologics	+3.16%	-2.49%	-5.31%	-3.45%	-73.30%
RPTX Repare Therapeutics	+0.33%	+1.32%	+2.67%	+7.69%	-46.71%
VNRX VolitionRx	-2.65%	+0.32%	-6.40%	+33.60%	+18.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLRX BioLineRx	3.0349 of 5 stars	3.8	3.0	3.3	0.0	1.3
OTLK Oncobiologics	2.6119 of 5 stars	3.4	4.0	3.1	0.0	0.6
RPTX Repare Therapeutics	3.299 of 5 stars	3.3	5.0	2.6	2.5	0.6
VNRX VolitionRx	2.4676 of 5 stars	3.5	0.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	3.50	Strong Buy	$26.00	593.33% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	359.33% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	188.46% Upside
VNRX VolitionRx	3.00	Buy	$3.50	464.52% Upside

Current Analyst Ratings Breakdown

Latest BLRX, OTLK, VNRX, and RPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/17/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/30/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/28/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$28.94M	0.55	N/A	N/A	$4.04 per share	0.93
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
RPTX Repare Therapeutics	$53.48M	1.25	N/A	N/A	$2.57 per share	0.61
VNRX VolitionRx	$1.31M	49.27	N/A	N/A	($0.11) per share	-5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$9.22M	-$8.80	N/A	N/A	N/A	-15.21%	-23.93%	-6.80%	8/14/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	N/A
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest BLRX, OTLK, VNRX, and RPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BLRX BioLineRx	-$0.35	N/A	N/A	N/A	$0.66 million	N/A
8/13/2025	Q3 2025	OTLK Oncobiologics	-$0.42	N/A	N/A	N/A	$1.66 million	N/A
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million
5/27/2025	Q1 2025	BLRX BioLineRx	-$0.84	$1.39	+$2.23	$1.39	$7.72 million	$11.75 million
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.37	2.27	2.04
OTLK Oncobiologics	N/A	0.72	0.57
RPTX Repare Therapeutics	N/A	6.30	7.42
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
OTLK Oncobiologics	11.20%
RPTX Repare Therapeutics	85.09%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
OTLK Oncobiologics	4.80%
RPTX Repare Therapeutics	11.50%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	40	4.26 million	4.22 million	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
RPTX Repare Therapeutics	180	42.96 million	37.96 million	Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

BLRX, OTLK, VNRX, and RPTX Headlines

Recent News About These Companies

VolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's What Happened

August 9 at 4:54 AM | marketbeat.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...

August 8, 2025 | gurufocus.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8, 2025 | prnewswire.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

August 7, 2025 | marketbeat.com

Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

August 7, 2025 | marketbeat.com

VolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in Stock

August 7, 2025 | insidertrades.com

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025 | prnewswire.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, OTLK, VNRX, and RPTX Company Descriptions

BioLineRx NASDAQ:BLRX

$3.75 +0.03 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$3.78 +0.03 (+0.80%)

As of 06:30 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Oncobiologics NASDAQ:OTLK

$2.09 +0.13 (+6.63%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.03 (+1.44%)

As of 07:59 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Repare Therapeutics NASDAQ:RPTX

$1.56 +0.02 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 -0.03 (-1.60%)

As of 07:45 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

VolitionRx NYSE:VNRX

$0.62 0.00 (0.00%)

Closing price 03:58 PM Eastern

Extended Trading

$0.62 +0.00 (+0.65%)

As of 06:53 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time